Article Text

Download PDFPDF
Selegiline: new evidence for long-term benefit


In the update of selegiline (27 November 1989, page 95) we concluded that the drug had not been proven to delay the progression of Parkinson’s disease. Interim results from the large DATATOP trial now provides strong evidence that selegiline 10mg/day delays the untreated disease (The Parkinson Study Group. N Engl J. Med 1989; 321: 1364–71). The report appeared after we had gone to press.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.